{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:54:06Z","timestamp":1780671246403,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jfma.2022.01.003","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T17:49:34Z","timestamp":1642009774000},"page":"1167-1173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Immunotherapy in anaplastic thyroid cancer: Case series"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7424-1358","authenticated-orcid":false,"given":"Shyang-Rong","family":"Shih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6781-9091","authenticated-orcid":false,"given":"Kuan-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan-Chyr","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0266-9627","authenticated-orcid":false,"given":"Kuen-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Nan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Feng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2573-5789","authenticated-orcid":false,"given":"Chia-Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2022.01.003_bib1","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1089\/thy.2012.0302","article-title":"American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer","volume":"22","author":"Smallridge","year":"2012","journal-title":"Thyroid"},{"key":"10.1016\/j.jfma.2022.01.003_bib2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrendo.2017.76","article-title":"Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies","volume":"13","author":"Molinaro","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jfma.2022.01.003_bib3","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/ERC-17-0435","article-title":"Anaplastic thyroid carcinoma: review of treatment protocols","volume":"25","author":"Tiedje","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.jfma.2022.01.003_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/14737140.2018.1417845","article-title":"Current and future immunotherapies for thyroid cancer","volume":"18","author":"Antonelli","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jfma.2022.01.003_bib5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2213-8587(16)30277-7","article-title":"Leveraging the immune system to treat advanced thyroid cancers","volume":"5","author":"French","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jfma.2022.01.003_bib6","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1089\/thy.2018.0060","article-title":"Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma","volume":"28","author":"Cabanillas","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.jfma.2022.01.003_bib7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40425-018-0378-y","article-title":"Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma","volume":"6","author":"Iyer","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jfma.2022.01.003_bib8","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1634\/theoncologist.2017-0096","article-title":"Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer","volume":"22","author":"Kollipara","year":"2017","journal-title":"Oncol"},{"key":"10.1016\/j.jfma.2022.01.003_bib9","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 blockade in anaplastic thyroid carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2022.01.003_bib10","doi-asserted-by":"crossref","first-page":"6513","DOI":"10.1200\/JCO.2020.38.15_suppl.6513","article-title":"A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC)","volume":"38","author":"Lorch","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2022.01.003_bib11","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1089\/thy.2019.0086","article-title":"A phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer","volume":"29","author":"Chintakuntlawar","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.jfma.2022.01.003_bib12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fonc.2017.00025","article-title":"Lenvatinib for anaplastic thyroid cancer","volume":"7","author":"Tahara","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.jfma.2022.01.003_bib13","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1200\/JCO.20.03093","article-title":"Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer","volume":"39","author":"Wirth","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2022.01.003_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12943-018-0786-0","article-title":"Novel targeted therapies and immunotherapy for advanced thyroid cancers","volume":"17","author":"Naoum","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jfma.2022.01.003_bib15","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.jfma.2022.01.003_bib16","doi-asserted-by":"crossref","first-page":"djv414","DOI":"10.1093\/jnci\/djv414","article-title":"Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors: current perspectives","volume":"108","author":"Atkins","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jfma.2022.01.003_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2022.01.003_bib18","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.1200\/JCO.2020.38.15_suppl.6514","article-title":"Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC)","volume":"38","author":"Cabanillas","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2022.01.003_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.intimp.2018.03.018","article-title":"Pseudoprogression and hyperprogression after checkpoint blockade","volume":"58","author":"Wang","year":"2018","journal-title":"Int Immunopharm"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664622000031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664622000031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:47:24Z","timestamp":1760539644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664622000031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0929664622000031"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2022.01.003","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in anaplastic thyroid cancer: Case series","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2022.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}